Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19508750 | 0.92 | KLK5 (0.51) | PPARAACEPPARGCTSSCTSL | |
| SCHEMBL3429311 | 0.90 | ACE (0.56) | MAPK1PPARAACEPPARGCTSS | |
| SCHEMBL17642069 | 0.90 | ACE (0.56) | MAPK1PPARAACEPPARGCTSS | |
| SCHEMBL9871376 | 0.87 | TACR1 (0.53) | MAPTPOLBACETACR1TRHDE | |
| SCHEMBL30064788 | 0.86 | CTSS (0.47) | ACECTSSCTSLCTSBCTSK | |
| SCHEMBL5361692 | 0.85 | SIRT2 (0.53) | MAPTPOLBMAPK1PPARAKLK7 | |
| SCHEMBL31035995 | 0.83 | TRHDE (0.52) | PPARAPPARGCTSSTACR1CTSL | |
| SCHEMBL8121406 | 0.83 | CTSS (0.52) | CTSSCTSLCTSBCTSK | |
| SCHEMBL8121405 | 0.83 | CTSS (0.52) | CTSSCTSLCTSBCTSK | |
| SCHEMBL18183914 | 0.82 | PTPN1 (0.49) | MAPTPOLBMAPK1PPARAACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| EP-1309552-A4 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | UNIV QUEENSLAND (AU) | 2005-07-20 | — | — | EP | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
| EP-1309552-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002008189-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | MAPT 3460/4885POLB 1265/4885MAPK1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.